|
Synonyms: HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417
Compound class:
Antibody
Comment: Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) [2] that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.
|
| Immunopharmacology Comments |
| This antibody targets the cell adhesion molecule P-selectin which is expressed by platelets and endothelial cells that have been activated by injury and/or inflammation. It forms a functional link between inflammation, platelets and endothelial damage. |
